As secondary outcomes, exposure to metformin was associated with significantly lower mean birth weight, and compared with insulin, no differences were observed for the other secondary outcomes (LGA, SGA, preterm birth, neonatal mortality, neonatal hypoglycemia and hyperglycemia, and major congenital anomalies). The gene discussed is INS; the disease is Hypoglycemia.